Workflow
Novavax Appoints Charles Newton to Board of Directors
NovavaxNovavax(US:NVAX) Prnewswire·2025-04-29 12:00

Core Insights - Novavax, Inc. has appointed Charles Newton as an independent director to its board, bringing extensive experience in public markets and healthcare investment banking [1][2] - The company aims to leverage Mr. Newton's expertise to enhance its corporate growth strategy, focusing on strategic partnerships for its R&D assets and Matrix-M® adjuvant [2][3] Company Overview - Novavax is dedicated to addressing significant health challenges through its scientific expertise in vaccines and advanced technology platforms, including protein-based nanoparticles and the Matrix-M adjuvant [4] - The company's growth strategy emphasizes building diversified partnerships via out-licensing its technology and vaccine assets earlier in the development process, with a focus on infectious diseases and potential expansion into other areas [4]